EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Exploratory Time‐Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non‐Deficient or Unknown Metastatic Castration‐Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO ‐2 Trial

Shugo Yajima, Soichiro Yoshida iD, Wei Chen, Hiroshi Fukushima, Hajime Tanaka iD, Hiroyuki Sato iD, Akihiro Hirakawa iD, Hitoshi Masuda, Yasuhisa Fujii

International Journal of Urology · 2026

DOI: 10.1111/iju.70582 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift International Journal of Urology, 2026. Verfasst von Shugo Yajima und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, National Cancer Center Hospital East, Chiba, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Phenylthiohydantoin, Phthalazines, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Talazoparib plus enzalutamide improved overall survival (OS) in the biomarker‐unselected TALAPRO‐2 population, but OS benefit was not statistically significant in the homologous recombination repair (HRR) non‐deficient or unknown subgroup, whereas radiographic progression‐free survival (rPFS) was prolonged. We explored time‐dependent patterns in estimated treatment effects in this subgroup.

Methods

Approximate individual‐level data for 636 patients were reconstructed from published Kaplan–Meier curves; original trial‐level patient data were unavailable. The proportional hazards assumption was assessed using Schoenfeld residuals and log–log plots. Interval‐specific hazard ratios (HRs) were estimated using piecewise Cox models. A treatment‐by‐log(time + 1) interaction was evaluated formally. Sensitivity analyses included alternative interval schemes, landmark analyses, restricted mean survival time (RMST), and descriptive application of the same piecewise framework to the HRR‐deficient subgroup.

Results

The proportional hazards assumption was not rejected for OS ( p = 0.63) or rPFS ( p = 0.37). For OS, the 36–48‐month interval showed a nominally lower hazard with talazoparib (HR 0.59; 95% confidence interval [CI] 0.36–0.97; nominal p = 0.039). For rPFS, the lowest HR occurred at 0–6 months (HR 0.56; 95% CI 0.37–0.86; p = 0.008). Treatment‐by‐log(time + 1) interactions were not statistically significant for OS ( p = 0.44) or rPFS ( p = 0.12).

Conclusions

This reconstructed‐data post hoc analysis suggested exploratory time‐dependent patterns in effect estimates without formal evidence of a time‐varying treatment effect. Findings are descriptive, hypothesis‐generating, and should not be extrapolated to molecularly confirmed HRR‐proficient disease. Trial Registration ClinicalTrials.gov : NCT03395197

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsPhenylthiohydantoinPhthalazinesProstatic Neoplasms, Castration-ResistantAgedHumansMaleBenzamidesKaplan-Meier EstimateNitrilesProgression-Free SurvivalProportional Hazards ModelsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

metastatic castration‐resistant prostate cancerpoly(ADP‐ribose) polymerase inhibitorstalazoparib

Substanzen

BenzamidesenzalutamideNitrilesPhenylthiohydantoinPhthalazinestalazoparib

Autor:innen und Institutionen

  • Department of Urology, National Cancer Center Hospital East, Chiba, Japan.
  • Department of Urology, Institute of Science Tokyo, Tokyo, Japan.
  • Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.

ORCID-Profile: Soichiro Yoshida, Hajime Tanaka, Hiroyuki Sato, Akihiro Hirakawa

Zitieren

APA

Yajima, S., Yoshida, S., Chen, W., Fukushima, H., Tanaka, H., Sato, H., Hirakawa, A., Masuda, H., & Fujii, Y. (2026). Exploratory Time‐Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non‐Deficient or Unknown Metastatic Castration‐Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO ‐2 Trial. International Journal of Urology. https://doi.org/10.1111/iju.70582

Vancouver

Yajima S, Yoshida S, Chen W, Fukushima H, Tanaka H, Sato H, et al. Exploratory Time‐Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non‐Deficient or Unknown Metastatic Castration‐Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO ‐2 Trial. International Journal of Urology. 2026. doi:10.1111/iju.70582

BibTeX
@article{Yajima2026,
  author = {Yajima, Shugo and Yoshida, Soichiro and Chen, Wei and Fukushima, Hiroshi and Tanaka, Hajime and Sato, Hiroyuki and Hirakawa, Akihiro and Masuda, Hitoshi and Fujii, Yasuhisa},
  title = {Exploratory Time‐Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non‐Deficient or Unknown Metastatic Castration‐Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO ‐2 Trial},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70582}
}
Kostenlos starten →